GlassScriptPhysician profile
Matthew E A Clarke
NPI 1528315835
$1,566.56
in general payments reported to CMS, 2019-2025
24 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $512 · 2021: $44.02 · 2022: $20.42 · 2023: $178 · 2024: $176 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522 · Long Term Medical Supply Or Device Loan: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.16 |
| Long Term Medical Supply Or Device Loan | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $243.58 | 2019-2024 | Freestyle Copilot, Freestyle Libre 3 |
| Lilly USA, LLC | $185.55 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $145.39 | 2023-2025 | Cresemba |
| Novo Nordisk INC | $136.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Ultragenyx Pharmaceutical INC. | $130.32 | 2019-2020 | |
| Corcept Therapeutics | $101.00 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.58 | 2019-2025 | Jardiance |
| Amgen INC. | $81.12 | 2019-2025 | Tepezza, Prolia, Evenity |
| Silk Road Medical, INC. | $79.70 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Janssen Pharmaceuticals, INC | $43.49 | 2019-2020 | |
| Antares Pharma, INC. | $38.61 | 2019 | |
| Tandem Diabetes Care, INC. | $32.36 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $30.59 | 2019 | |
| Merck Sharp & Dohme LLC | $27.69 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $23.60 | 2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $22.02 | 2025 | Yorvipath |
| Valeritas, INC. | $21.94 | 2019 | |
| Ibsa Pharma INC. | $21.39 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $20.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.42 | 2022 | |
| Kyowa Kirin, INC. | $20.25 | 2025 | |
| Ascensia Diabetes Care US INC. | $18.43 | 2023 | |
| Mannkind Corporation | $17.62 | 2020 | |
| Dexcom, INC. | $14.25 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.